StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)

Close on Nov 17, 2026Market cap $10.23MP/E –Yield –

TScan Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

TScan Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $97.03M, down 17.8% year over year. For fiscal 2025 it was $114.15M, up 6.3% from the year before. The highest annual figure on record is $114.15M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$114.15M+6.3%
FY2024Dec 31, 2024$107.35M+21.8%
FY2023Dec 31, 2023$88.15M+47.4%
FY2022Dec 31, 2022$59.82M+33.1%
FY2021Dec 31, 2021$44.95M+118.5%
FY2020Dec 31, 2020$20.58M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$23.40M-28.3%
Q1 FY2026Mar 31, 2026$21.90M-26.5%
Q4 FY2025Dec 31, 2025$20.04M-31.7%
Q3 FY2025Sep 30, 2025$31.69M+20.7%
Q2 FY2025Jun 30, 2025$32.63M+21.4%
Q1 FY2025Mar 31, 2025$29.79M+19.8%
Q4 FY2024Dec 31, 2024$29.35M+31.0%
Q3 FY2024Sep 30, 2024$26.26M+15.5%
Q2 FY2024Jun 30, 2024$26.88M+26.6%
Q1 FY2024Mar 31, 2024$24.86M+14.1%
Q4 FY2023Dec 31, 2023$22.41M+43.6%
Q3 FY2023Sep 30, 2023$22.74M+51.3%
Q2 FY2023Jun 30, 2023$21.23M+46.5%
Q1 FY2023Mar 31, 2023$21.78M+48.3%
Q4 FY2022Dec 31, 2022$15.60M+23.8%
Q3 FY2022Sep 30, 2022$15.03M+5.8%
Q2 FY2022Jun 30, 2022$14.49M+34.2%
Q1 FY2022Mar 31, 2022$14.69M+100.2%
Q4 FY2021Dec 31, 2021$12.61M+111.4%
Q3 FY2021Sep 30, 2021$14.21M+144.4%
Q2 FY2021Jun 30, 2021$10.80M+139.9%
Q1 FY2021Mar 31, 2021$7.34M–
Q4 FY2020Dec 31, 2020$5.96M–
Q3 FY2020Sep 30, 2020$5.81M–
Q2 FY2020Jun 30, 2020$4.50M–

More TScan Therapeutics figures

See a number that looks wrong?